Private company Defender Pharmaceuticals has had its submission for a new motion sickness treatment rejected by the US Food and Drug Administration.
Based in Missouri, USA, the firm is working on an intranasal formulation of scopolamine, known as DPI-386, for the prevention of nausea and vomiting induced by motion in adults.
The therapy, which is designed for astronauts and people in the navy, is being developed in collaboration with the US Naval Medical Research Unit (NAMRU-D) and the National Aeronautics and Space Administration (NASA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze